contraindications for glp 1 to 🕰️60-second review: Mnemonics and Updates in GLP -1 agonists in glp 1 receptor agonists contraindications

Please remember this product may take up to 3 months for you to see craving and gut health improvement

Based on this review, evidence from head-to-head and insulin-comparator trials demonstrates that dual GIP/GLP-1 co-agonism consistently overcomes metabolic plateaus that result from single-pathway therapy, producing superior glycated hemoglobin reduction, bariatric-level weight loss (up to 25.3%), and robust macrovascular and heart failure protection, including a 38% reduction in composite cardiovascular risk among patients with heart failure with preserved ejection fraction (HFpEF)

Purpose of the Review Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management

Janet Klein, MS RDN, CDN, CDCES, Bariatric Surgery and Obesity Medicine Program Director